GO:0016507 mitochondrial fatty acid beta-oxidation multienzyme complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016507 describes a mitochondrial matrix multienzyme complex with three fatty acid beta-oxidation activities distributed across alpha and beta subunits.
• The alpha subunit carries enoyl-CoA hydratase (ECH) and 3-hydroxyacyl-CoA dehydrogenase (HACD) activities, while the beta subunit carries acetyl-CoA C-acyltransferase (KACT)/thiolase activity.
• The complex is also known as the trifunctional enzyme or fatty acid beta-oxidation multienzyme complex and enables substrate channelling between active sites.
• Defects in mitochondrial fatty acid beta-oxidation cause inborn errors of metabolism that can present with hypoglycaemia and cardiomyopathy.
• HADHB, the beta subunit of the complex, has been identified as a potential prognostic predictor in malignant lymphoma.
• Studying this complex requires integrated structural, biochemical, and CRISPR-based approaches to resolve subunit-specific functions.
Description
GO:0016507, the mitochondrial fatty acid beta-oxidation multienzyme complex, is a cellular component that catalyzes three consecutive steps of the fatty acid beta-oxidation cycle within the mitochondrial matrix. This complex is a classic example of metabolic channelling, in which sequential enzymatic activities are physically linked to optimize flux through a pathway. The complex is composed of two subunits: an alpha subunit that contains enoyl-CoA hydratase (ECH) and 3-hydroxyacyl-CoA dehydrogenase (HACD) activities, and a beta subunit that contains acetyl-CoA C-acyltransferase (KACT)/thiolase activity. Because fatty acid beta-oxidation is essential for energy production, defects in this complex lead to severe metabolic disorders, including hypoglycaemia and cardiomyopathy in children. Researchers study GO:0016507 to understand mitochondrial energy metabolism, substrate channelling, and the molecular basis of inherited fatty acid oxidation disorders. The complex has been structurally and biochemically characterized in bacterial and mitochondrial systems, providing a framework for understanding its assembly and catalytic mechanism.
mitochondrial fatty acid beta-oxidation multienzyme complex At A Glance
| GO ID | GO:0016507 |
|---|---|
| GO term | mitochondrial fatty acid beta-oxidation multienzyme complex |
| Ontology | cellular_component |
| Synonym | fatty acid beta-oxidation multienzyme complex; trifunctional enzyme |
| Major function | Catalyzes three steps of the fatty acid beta-oxidation cycle within the mitochondrial matrix |
| Subunit composition | Alpha subunit (ECH and HACD activities) and beta subunit (KACT/thiolase activity) |
| Subcellular location | Mitochondrial matrix |
| Pathway context | Fatty acid beta-oxidation |
| Related disease | Inborn errors of mitochondrial fatty acid oxidation; hypoglycaemia in children |
What Is GO:0016507?
The mitochondrial fatty acid beta-oxidation multienzyme complex (GO:0016507) is a multienzyme complex located in the mitochondrial matrix that possesses three enzymatic activities distributed across two subunits, alpha and beta. The alpha subunit comprises enoyl-CoA hydratase (ECH) and 3-hydroxyacyl-CoA dehydrogenase (HACD) activities, and the beta subunit contains acetyl-CoA C-acyltransferase (KACT)/thiolase activity. Together, these activities catalyze three steps of the fatty acid beta-oxidation cycle.
Why Is mitochondrial fatty acid beta-oxidation multienzyme complex Important in Cell Biology?
GO:0016507 is important because it represents a central node in mitochondrial energy metabolism, and its dysfunction is directly linked to severe human diseases. Inborn errors of mitochondrial fatty acid oxidation, including defects in the multienzyme complex, can cause hypoglycaemia, cardiomyopathy, and sudden death in children. The complex also serves as a paradigm for understanding substrate channelling, a mechanism that enhances metabolic efficiency by directing intermediates between active sites without releasing them into the bulk solvent. Furthermore, the beta subunit HADHB has been implicated as a prognostic predictor in malignant lymphoma, suggesting that this metabolic complex has roles beyond classical energy production. Studying GO:0016507 therefore has implications for inherited metabolic disorders, cancer biology, and fundamental cell biology.
• Defects in the complex cause inborn errors of mitochondrial fatty acid oxidation, a group of life-threatening metabolic disorders.
• The complex is essential for energy production during fasting and high-energy demand states.
• It exemplifies substrate channelling, a fundamental mechanism in metabolic organization.
• HADHB, the beta subunit, is a potential prognostic marker in malignant lymphoma.
• The complex is a target for understanding hypoglycaemia in children.
• Structural studies of the complex inform rational drug design for metabolic diseases.
• It provides a model for studying multienzyme complex assembly and regulation.
• Comparative studies in fungi and bacteria reveal evolutionary conservation of beta-oxidation.
• Peroxisomal beta-oxidation, which shares some activities, highlights the unique role of the mitochondrial complex.
• CRISPR-based models of complex subunits enable functional dissection of each enzymatic activity.
What Happens During mitochondrial fatty acid beta-oxidation multienzyme complex?
Step 1: Enoyl-CoA hydratase (ECH) activity
In simple terms: The first step adds water to a double bond in the fatty acid chain.
The alpha subunit of the complex possesses enoyl-CoA hydratase activity, which catalyzes the hydration of trans-2-enoyl-CoA to L-3-hydroxyacyl-CoA. This reaction is the second step of the beta-oxidation cycle, following acyl-CoA dehydrogenase. Structural studies of the multienzyme complex have revealed that the active site of ECH is positioned to receive substrates directly from the preceding enzyme via a channelling mechanism.
Step 2: 3-Hydroxyacyl-CoA dehydrogenase (HACD) activity
In simple terms: The second step removes hydrogen atoms to form a keto group.
The alpha subunit also contains 3-hydroxyacyl-CoA dehydrogenase activity, which catalyzes the NAD+-dependent oxidation of L-3-hydroxyacyl-CoA to 3-ketoacyl-CoA. This reaction constitutes the third step of the beta-oxidation cycle. The close proximity of ECH and HACD active sites within the alpha subunit facilitates efficient substrate channelling, as demonstrated by structural and biochemical analyses.
Step 3: Acetyl-CoA C-acyltransferase (KACT)/thiolase activity
In simple terms: The third step cleaves the fatty acid chain to release acetyl-CoA.
The beta subunit of the complex contains acetyl-CoA C-acyltransferase (KACT)/thiolase activity, which catalyzes the thiolytic cleavage of 3-ketoacyl-CoA to acetyl-CoA and a shortened acyl-CoA. This is the final step of each beta-oxidation cycle. The beta subunit is encoded by HADHB in humans, and its activity is essential for the complete oxidation of fatty acids.
Substrate channelling and metabolic efficiency
In simple terms: The complex passes intermediates directly between active sites without releasing them.
The mitochondrial fatty acid beta-oxidation multienzyme complex is a classic example of substrate channelling, where intermediates of the beta-oxidation cycle are transferred directly from one active site to the next without diffusing into the mitochondrial matrix. This mechanism increases catalytic efficiency and protects reactive intermediates. Structural studies of the complex from Pseudomonas fragi and mitochondrial sources have provided insights into the molecular basis of channelling.
Integration with the beta-oxidation spiral
In simple terms: The complex handles three of the four steps in each round of fatty acid breakdown.
The beta-oxidation spiral consists of four reactions: oxidation, hydration, dehydrogenation, and thiolysis. The multienzyme complex catalyzes the hydration, dehydrogenation, and thiolysis steps, while acyl-CoA dehydrogenase catalyzes the first oxidation step. This organization ensures that the entire cycle operates efficiently within the mitochondrial matrix. The complex is therefore a key component of mitochondrial energy metabolism.
Key Genes Involved in GO:0016507 mitochondrial fatty acid beta-oxidation multienzyme complex
The following genes encode proteins that are either subunits of the mitochondrial fatty acid beta-oxidation multienzyme complex or are closely associated with its function and regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HADHA | Alpha subunit of the mitochondrial trifunctional enzyme; carries ECH and HACD activities | Mutations cause mitochondrial trifunctional protein deficiency; target for metabolic disease models |
| HADHB | Beta subunit of the mitochondrial trifunctional enzyme; carries KACT/thiolase activity | Prognostic predictor in malignant lymphoma; mutations cause trifunctional protein deficiency |
| ACADVL | Very long-chain acyl-CoA dehydrogenase; first step of beta-oxidation | Defects cause VLCAD deficiency; interacts with the complex |
| ACADM | Medium-chain acyl-CoA dehydrogenase | Defects cause MCAD deficiency; model for beta-oxidation disorders |
| CPT1A | Carnitine palmitoyltransferase 1A; transports fatty acids into mitochondria | Rate-limiting for beta-oxidation; target for metabolic regulation studies |
| CPT2 | Carnitine palmitoyltransferase 2; inner membrane transport | Defects cause CPT II deficiency; relevant to hypoglycaemia |
| SLC25A20 | Carnitine-acylcarnitine translocase | Defects cause carnitine-acylcarnitine translocase deficiency |
| ETFA | Electron transfer flavoprotein alpha subunit | Links beta-oxidation to respiratory chain; defects cause glutaric acidemia type II |
| ETFB | Electron transfer flavoprotein beta subunit | Same as ETFA; relevant to beta-oxidation electron transfer |
| ETFDH | Electron transfer flavoprotein dehydrogenase | Defects cause multiple acyl-CoA dehydrogenase deficiency |
| HADH | Short-chain 3-hydroxyacyl-CoA dehydrogenase | Defects cause hyperinsulinism; related to HACD activity |
| ACAA2 | Mitochondrial 3-ketoacyl-CoA thiolase | Alternative thiolase; relevant to complex redundancy |
| PPARA | Peroxisome proliferator-activated receptor alpha | Regulates fatty acid oxidation gene expression |
| PPARGC1A | PGC-1alpha; coactivator of mitochondrial biogenesis | Regulates mitochondrial fatty acid oxidation capacity |
| SIRT1 | NAD+-dependent deacetylase | Regulates fatty acid oxidation via deacetylation |
| AMPK | AMP-activated protein kinase | Energy sensor that promotes fatty acid oxidation |
| HADHA | Alpha subunit; also has long-chain enoyl-CoA hydratase activity | Structural studies of channelling |
| HADHB | Beta subunit; thiolase activity | Biochemical reconstitution studies |
How Is mitochondrial fatty acid beta-oxidation multienzyme complex Regulated?
The mitochondrial fatty acid beta-oxidation multienzyme complex is regulated at multiple levels. Transcriptional regulation is mediated by nuclear receptors such as PPARA, which controls the expression of genes encoding beta-oxidation enzymes in response to fasting or high-fat diets. Post-translational modifications, including acetylation and phosphorylation, modulate the activity of beta-oxidation enzymes, with SIRT1 and AMPK playing key roles in sensing energy status. The complex itself may be regulated by substrate availability and by the redox state of the mitochondrial matrix. Additionally, the expression of HADHB, the beta subunit, has been linked to prognosis in malignant lymphoma, suggesting that its regulation may be altered in cancer.
mitochondrial fatty acid beta-oxidation multienzyme complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HADHA | Mitochondrial trifunctional protein deficiency; hypoglycaemia, cardiomyopathy | HADHA knockout cell line; patient-derived fibroblasts |
| HADHB | Mitochondrial trifunctional protein deficiency; malignant lymphoma prognosis | HADHB knockout and overexpression models |
| ACADM | Medium-chain acyl-CoA dehydrogenase deficiency | ACADM knockout mouse; CRISPR point mutation |
| CPT2 | Carnitine palmitoyltransferase II deficiency; hypoglycaemia | CPT2 knockout cell line; point mutation knock-in |
| HADH | Hyperinsulinism; short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency | HADH knockout models |
Inborn errors of mitochondrial fatty acid oxidation
Defects in the mitochondrial fatty acid beta-oxidation multienzyme complex cause inborn errors of metabolism that can present with hypoglycaemia, cardiomyopathy, and sudden death in children. These disorders are inherited in an autosomal recessive pattern and are caused by mutations in HADHA or HADHB, leading to deficient activity of the trifunctional enzyme. Early diagnosis and dietary management are critical for patient survival.
Hypoglycaemia in children
Mitochondrial fatty acid beta-oxidation disorders, including those affecting the multienzyme complex, are important causes of hypoglycaemia in children. During fasting, fatty acid oxidation is a major source of energy, and defects in the complex impair the ability to maintain normoglycaemia. This can lead to severe hypoglycaemic episodes and metabolic decompensation.
Malignant lymphoma
HADHB, the beta subunit of the mitochondrial fatty acid beta-oxidation multienzyme complex, has been identified as a potential prognostic predictor in malignant lymphoma. This suggests that altered fatty acid oxidation may contribute to lymphoma biology and that HADHB expression could serve as a biomarker. The mechanism linking HADHB to lymphoma prognosis is an active area of research.
Peroxisomal beta-oxidation and polyunsaturated fatty acids
While the mitochondrial multienzyme complex is distinct from peroxisomal beta-oxidation, both pathways contribute to fatty acid metabolism. Peroxisomal beta-oxidation is involved in the chain shortening of polyunsaturated fatty acids, and defects in this pathway cause distinct disorders. Understanding the interplay between mitochondrial and peroxisomal oxidation is important for a complete picture of fatty acid metabolism.
From mitochondrial fatty acid beta-oxidation multienzyme complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of HADHA loss on beta-oxidation flux? | HADHA knockout cell line (CRISPR-Cas9) |
| How does a specific HADHB mutation affect thiolase activity? | HADHB point mutation knock-in cell line |
| Can wild-type HADHB rescue the phenotype of HADHB-deficient cells? | HADHB knock-in (tagged) overexpression |
| What is the role of substrate channelling in the complex? | Reconstitution with purified subunits and structural analysis |
| How does HADHB expression affect lymphoma cell proliferation? | HADHB overexpression and knockout in lymphoma cell lines |
| What are the metabolic consequences of complex deficiency? | Patient-derived fibroblasts and CRISPR-corrected isogenic controls |
How to Study the mitochondrial fatty acid beta-oxidation multienzyme complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Three-dimensional structure of the complex | Understanding subunit arrangement and channelling |
| Enzyme activity assays | ECH, HACD, and KACT activities | Functional characterization of mutant subunits |
| Acylcarnitine profiling | Accumulation of fatty acid oxidation intermediates | Diagnosis of inborn errors of beta-oxidation |
| RNA-seq | Gene expression changes | Identifying compensatory pathways in knockout models |
| Proteomics | Protein abundance and modifications | Quantifying HADHB expression in lymphoma |
| Fatty acid oxidation flux assay | Rate of beta-oxidation | Validating CRISPR models |
| CRISPR-Cas9 knockout | Loss of gene function | Creating isogenic models of complex deficiency |
| Site-directed mutagenesis | Specific amino acid changes | Dissecting catalytic residues in HADHA/HADHB |
Structural biology and biochemistry
Structural studies using X-ray crystallography and cryo-electron microscopy have revealed the architecture of the mitochondrial fatty acid beta-oxidation multienzyme complex, including the arrangement of alpha and beta subunits and the substrate channelling mechanism. Biochemical reconstitution assays with purified subunits are used to measure individual enzymatic activities (ECH, HACD, KACT) and overall beta-oxidation flux.
Genomic and transcriptomic approaches
RNA-seq and targeted sequencing can identify mutations in HADHA and HADHB in patients with suspected fatty acid oxidation disorders. Transcriptomic profiling of tissues or cell lines with CRISPR-engineered mutations in complex subunits can reveal compensatory changes in related metabolic pathways.
Proteomics and metabolomics
Mass spectrometry-based proteomics can quantify the abundance of complex subunits and their post-translational modifications. Metabolomics, including acylcarnitine profiling, is a key diagnostic tool for fatty acid oxidation disorders and can be used to assess the functional impact of CRISPR edits.
Functional assays for beta-oxidation
Radioactive or fluorescent fatty acid oxidation assays in intact cells or isolated mitochondria measure the flux through the beta-oxidation pathway. These assays are essential for validating the functional consequences of CRISPR-mediated knockout or point mutations in complex subunits.
How CRISPR Can Be Used to Study GO:0016507 mitochondrial fatty acid beta-oxidation multienzyme complex
Knockout
CRISPR-Cas9 knockout of HADHA or HADHB can create isogenic cell models of mitochondrial trifunctional protein deficiency. These models are used to study the metabolic consequences of complex loss, including impaired beta-oxidation flux and altered acylcarnitine profiles. Knockout of the beta subunit HADHB in lymphoma cell lines can test its role in cancer cell proliferation and prognosis.
Point Mutation
CRISPR-mediated point mutations can introduce specific patient-derived missense mutations into HADHA or HADHB to dissect the functional impact of individual residues on enzymatic activities. For example, mutations in the thiolase active site of HADHB can be modeled to understand substrate binding and catalysis. These models are valuable for genotype-phenotype correlation studies.
Knock-in
Knock-in of tagged versions of HADHA or HADHB (e.g., GFP or FLAG) allows for live-cell imaging and affinity purification of the complex. This approach can reveal the subcellular localization and assembly dynamics of the multienzyme complex. Knock-in of wild-type HADHB can also rescue phenotypes in HADHB-deficient cells.
Overexpression
Overexpression of HADHA or HADHB using CRISPR activation or lentiviral vectors can increase beta-oxidation capacity and study the effects of complex abundance on metabolic flux. In lymphoma models, HADHB overexpression can test whether increased fatty acid oxidation promotes or suppresses tumor growth. Overexpression of the entire complex may also be used for structural studies.
How EDITGENE Supports mitochondrial fatty acid beta-oxidation multienzyme complex Research
Researchers studying mitochondrial fatty acid beta-oxidation multienzyme complex-related genes often need to determine whether a candidate gene is causally involved in metabolic dysfunction or disease progression. This requires precise genetic models that can isolate the contribution of individual subunits and their enzymatic activities. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for mitochondrial fatty acid beta-oxidation multienzyme complex research.
Frequently Asked Questions About mitochondrial fatty acid beta-oxidation multienzyme complex
What is GO:0016507?
GO:0016507 is the Gene Ontology term for the mitochondrial fatty acid beta-oxidation multienzyme complex, a mitochondrial matrix complex that catalyzes three steps of fatty acid beta-oxidation.
What genes are involved in the mitochondrial fatty acid beta-oxidation multienzyme complex?
The complex is composed of an alpha subunit encoded by HADHA and a beta subunit encoded by HADHB.
What is the function of the mitochondrial fatty acid beta-oxidation multienzyme complex?
It catalyzes the hydration, dehydrogenation, and thiolysis steps of the fatty acid beta-oxidation cycle, enabling energy production from fatty acids.
What diseases are associated with defects in this complex?
Defects cause inborn errors of mitochondrial fatty acid oxidation, which can present with hypoglycaemia, cardiomyopathy, and sudden death in children.
What is the role of HADHB in cancer?
HADHB has been identified as a potential prognostic predictor in malignant lymphoma.
How is the complex regulated?
It is regulated by nuclear receptors such as PPARA, and by post-translational modifications involving SIRT1 and AMPK.
What is substrate channelling in this complex?
Substrate channelling is the direct transfer of intermediates between active sites within the complex, enhancing metabolic efficiency.
What model systems are used to study this complex?
Model systems include CRISPR knockout cell lines, patient-derived fibroblasts, and purified enzyme reconstitution assays.
What are the symptoms of mitochondrial trifunctional protein deficiency?
Symptoms include hypoglycaemia, cardiomyopathy, and metabolic decompensation, often triggered by fasting or illness.
How can CRISPR help study this complex?
CRISPR can create knockout, point mutation, knock-in, and overexpression models to dissect the function of HADHA and HADHB.
Conclusion
The mitochondrial fatty acid beta-oxidation multienzyme complex (GO:0016507) is a central component of mitochondrial energy metabolism, catalyzing three steps of the beta-oxidation cycle through its alpha and beta subunits. Its dysfunction causes severe inherited metabolic disorders, and its beta subunit HADHB has been linked to cancer prognosis. Structural and biochemical studies have revealed a substrate channelling mechanism that optimizes metabolic flux. Continued research using CRISPR-based models will further elucidate the complex's roles in health and disease.
References
- 1. Vianey-Liaud C et al.. 1987. The inborn errors of mitochondrial fatty acid oxidation.. J Inherit Metab Dis 10 Suppl 1:159-200 PMID: 3119938
- 2. Taroni F et al.. 1996. Fatty acid mitochondrial beta-oxidation and hypoglycaemia in children.. Curr Opin Neurol 9(6):477-85 PMID: 9007409
- 3. Sekine Y et al.. 2022. HADHB, a fatty acid beta-oxidation enzyme, is a potential prognostic predictor in malignant lymphoma.. Pathology 54(3):286-293 PMID: 34531036
- 4. Ishikawa M et al.. 2004. Structural basis for channelling mechanism of a fatty acid beta-oxidation multienzyme complex.. EMBO J 23(14):2745-54 PMID: 15229654
- 5. Ishikawa M et al.. 1997. Reconstitution, morphology and crystallization of a fatty acid beta-oxidation multienzyme complex from Pseudomonas fragi.. Biochem J 328 ( Pt 3)(Pt 3):815-20 PMID: 9396725
- 6. Ishikawa M et al.. 2005. [Substrate-channelling mechanism of a fatty acid beta-oxidation multienzyme complex].. Tanpakushitsu Kakusan Koso 50(10 Suppl):1197-204 PMID: 16104585
- 7. Maggio-Hall LA et al.. 2004. Mitochondrial beta-oxidation in Aspergillus nidulans.. Mol Microbiol 54(5):1173-85 PMID: 15554960
- 8. Hiltunen JK et al.. 1996. Peroxisomal beta-oxidation and polyunsaturated fatty acids.. Ann N Y Acad Sci 804:116-28 PMID: 8993540
